PINK:DSRLF

Diasorin S.p.a Stock Predictions

> Medical - Diagnostics & Research

Buy DSRLF

*Your capital is at risk

$77.25

-3.75 (-4.63%)

At Close: Jul 10, 2026

Currently predicting for Mon, 13 Jul 2026

DSRLF Live board

Community Bull/Bear

Target Next close

Join the DSRLF prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

DSRLF Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For DSRLF

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

DSRLF Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT DIASORIN S.P.A.

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral inf...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
SRPT $17.02	11.34%	Jun 29
NMRK $15.02	1.20%	Jun 24
NESR $25.07	14.16%	Jun 23
CAG $13.43	2.98%	Jun 23
GIB $66.69	0.555%	Jun 12

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by